Mechanisms for Activation of Beige Adipose Tissue in Humans

Recruiting Phase 2 Interventional Study
PreDiabetes
Prior Safety Data This treatment has already been tested in at least one earlier human trial. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
35 – 65
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Basic Science
Participants needed
65 (estimated)
Sponsor
Philip Kern · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * BMI 27-45 * prediabetes (A1c 5.7-6.4) * impaired fasting glucose or impaired glucose tolerance Exclusion Criteria: * diabetes * chronic use of anti-diabetic medication * acute or chronic inflammatory condition * unstable medical condition * cancer * renal insufficiency * any…
Contacts

Zach Leicht

859-218-1397

zachary.leicht@uky.edu

CONTACT

Philip Kern, MD

859-218-1394

pake222@uky.edu

CONTACT